These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27025757)

  • 41. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extraction and Analysis of Peptidoglycan Cell Wall Precursors.
    Binda E; Carrano L; Marcone GL; Marinelli F
    Methods Mol Biol; 2016; 1440():153-70. PubMed ID: 27311671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycopeptide derivatives.
    Malabarba A; Ciabatti R
    Curr Med Chem; 2001 Dec; 8(14):1759-73. PubMed ID: 11562292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genomic-Led Discovery of a Novel Glycopeptide Antibiotic by
    Yushchuk O; Vior NM; Andreo-Vidal A; Berini F; Rückert C; Busche T; Binda E; Kalinowski J; Truman AW; Marinelli F
    ACS Chem Biol; 2021 May; 16(5):915-928. PubMed ID: 33913701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glycopeptide antibiotics: from conventional molecules to new derivatives.
    Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
    Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics.
    Billot-Klein D; Gutmann L; Bryant D; Bell D; Van Heijenoort J; Grewal J; Shlaes DM
    J Bacteriol; 1996 Aug; 178(15):4696-703. PubMed ID: 8755902
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Substrate Inhibition of VanA by d-Alanine Reduces Vancomycin Resistance in a VanX-Dependent Manner.
    van der Aart LT; Lemmens N; van Wamel WJ; van Wezel GP
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4930-9. PubMed ID: 27270282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vancomycin resistance VanS/VanR two-component systems.
    Hong HJ; Hutchings MI; Buttner MJ;
    Adv Exp Med Biol; 2008; 631():200-13. PubMed ID: 18792691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Requirement of the VanY and VanX D,D-peptidases for glycopeptide resistance in enterococci.
    Arthur M; Depardieu F; Cabanié L; Reynolds P; Courvalin P
    Mol Microbiol; 1998 Nov; 30(4):819-30. PubMed ID: 10094630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistance of enterococci to aminoglycosides and glycopeptides.
    Leclercq R; Dutka-Malen S; Brisson-Noël A; Molinas C; Derlot E; Arthur M; Duval J; Courvalin P
    Clin Infect Dis; 1992 Sep; 15(3):495-501. PubMed ID: 1520800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current perspectives on glycopeptide resistance.
    Woodford N; Johnson AP; Morrison D; Speller DC
    Clin Microbiol Rev; 1995 Oct; 8(4):585-615. PubMed ID: 8665471
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cross-Talking of Pathway-Specific Regulators in Glycopeptide Antibiotics (Teicoplanin and A40926) Production.
    Andreo-Vidal A; Yushchuk O; Marinelli F; Binda E
    Antibiotics (Basel); 2023 Mar; 12(4):. PubMed ID: 37107003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toward Single-Peak Dalbavancin Analogs through Biology and Chemistry.
    Alt S; Bernasconi A; Sosio M; Brunati C; Donadio S; Maffioli SI
    ACS Chem Biol; 2019 Mar; 14(3):356-360. PubMed ID: 30830742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of teicoplanin biosynthesis: refining the roles of tei cluster-situated regulatory genes.
    Yushchuk O; Horbal L; Ostash B; Marinelli F; Wohlleben W; Stegmann E; Fedorenko V
    Appl Microbiol Biotechnol; 2019 May; 103(10):4089-4102. PubMed ID: 30937499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms and implications of glycopeptide resistance in enterococci.
    Derlot E; Courvalin P
    Am J Med; 1991 Sep; 91(3B):82S-85S. PubMed ID: 1656750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of an inducible vancomycin resistance system in Streptomyces coelicolor reveals a novel gene (vanK) required for drug resistance.
    Hong HJ; Hutchings MI; Neu JM; Wright GD; Paget MS; Buttner MJ
    Mol Microbiol; 2004 May; 52(4):1107-21. PubMed ID: 15130128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Two-Component regulatory system with opposite effects on glycopeptide antibiotic biosynthesis and resistance.
    Alduina R; Tocchetti A; Costa S; Ferraro C; Cancemi P; Sosio M; Donadio S
    Sci Rep; 2020 Apr; 10(1):6200. PubMed ID: 32277112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Regulation mechanism of glycopeptide resistance expression].
    Ohno A; Ishii Y; Yamaguchi K
    Nihon Rinsho; 1997 May; 55(5):1206-12. PubMed ID: 9155176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.